Search the web
Welcome, Guest
[Sign Out, My Account]

Saturday, November 28 2015 8:11am ET - U.S. Markets Closed.
Industry Center
Industry Center > > UCB SA Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
UCB SA Company Profile
You see, UCB wants to be a world leader when it comes to treating ailments related to the immune and central nervous systems (CNS). The company manufacturers prescription drugs to treat Crohn's disease, epilepsy, and Parkinson's disease. UCB's top products include Cimzia for Crohn's disease,Vimpat to treat epilepsy, and Neupro for Parkinson's disease. The company also makes allergy blockbuster Zyrtec. UCB has operations in nearly 30 countries, and markets its products through an internal sales force and through strategic relationships with other pharmaceutical companies. Marketing, manufacturing, and development partners include AstraZeneca and Novartis. Financière de Tubize owns a majority stake in UCB.
Headlines for UCB SA
ZS Pharma Soars on $2.7B Buyout Offer from AstraZeneca - Mon Nov 9
Aerie (AERI) Posts Narrower-than-Expected Loss in Q3 - Wed Nov 4
Dr. Reddy's (RDY) Q2 Earnings Rise Y/Y, Biosimilars in Focus - Fri Oct 30
UCB SA – Value Analysis (US OTC:UCBJF) : October 28, 2015
- Wed Oct 28
More Headlines...
More on UCB SA
Quote Profile
Contact Information
Address: Allée De La Recherche 60
Bruxelles, Bruxelles-Capitale 1070, Belgium
Financial Highlights
Fiscal Year End:December
Revenue (2014):4064.60 M
Revenue Growth (1 yr):(-13.40%)
Employees (2014):8,684
Employee Growth (1 yr):(-0.50%)
Key People
Chairman: Gerhard N. Mayr
Chairman and CEO: Jean-Christophe Tellier
Vice Chair: Evelyn du Monceau
Industry Information
Top Competitors
Cephalon, Inc.

Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2015 Morningstar, Inc. All Rights Reserved. Company information © 2015 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2015, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?